Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.57 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.57 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.57 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.57 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830550 | 0.87 | — | — | |
| SCHEMBL27838 | 0.87 | — | — | |
| SCHEMBL196765 | 0.87 | CYP3A4 (0.73) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL29489425 | 0.87 | CYP3A4 (0.73) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL5543809 | 0.86 | ABL1 (0.58) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL4476485 | 0.86 | ABL1 (0.63) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| Hydrochloric Acid SCHEMBL28516238 | 0.85 | ACHE (0.54) | CYP3A4DYRK1ACLK4MAOBACHE | |
| SCHEMBL27592616 | 0.85 | ACHE (0.54) | CYP3A4CYP1A2CYP2A6DYRK1ACLK4 | |
| SCHEMBL27583381 | 0.85 | ACHE (0.54) | CYP3A4CYP1A2CYP2A6DYRK1ACLK4 | |
| Hydrogen Sulfide SCHEMBL28640169 | 0.84 | CYP3A4 (0.70) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7304055-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304056-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-20060264417-A1 | Succinoylamino lactams as inhibitors of a-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-11-23 | — | — | US | disclosed |
| US-7101870-B2 | Succinoylamino lactams as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-6962913-B2 | Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-03 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | disclosed |
| CN-1311779-A | Succinoylamino lactams as inhibitors and as A beta protein production | DU PONT PHARM CO (US) | 2001-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP3A4 1683/4885CYP1A1 1394/4885CYP1A2 659/4885 |
| US-20060264417-A1 | Succinoylamino lactams as inhibitors of a-beta protein production | BACE1, APH1A, APP | CYP3A4 2856/4885CYP1A1 2711/4885CYP1A2 2599/4885 |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | CYP3A4 2856/4885CYP1A1 2711/4885CYP1A2 2599/4885 |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | CYP3A4 2856/4885CYP1A1 2711/4885CYP1A2 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.